Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. / Stephens, J W; Bodvarsdottir, T B; Wareham, K; Prior, S L; Bracken, R M; Lowe, G D; Rumley, A; Dunseath, G; Luzio, S; Deacon, C F; Holst, Jens Juul; Bain, S C.
I: Diabetes Research and Clinical Practice, Bind 94, Nr. 2, 11.2011, s. 199-206.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus
AU - Stephens, J W
AU - Bodvarsdottir, T B
AU - Wareham, K
AU - Prior, S L
AU - Bracken, R M
AU - Lowe, G D
AU - Rumley, A
AU - Dunseath, G
AU - Luzio, S
AU - Deacon, C F
AU - Holst, Jens Juul
AU - Bain, S C
N1 - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
PY - 2011/11
Y1 - 2011/11
N2 - Aim: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin. Methods: A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120). Results: Significant improvements in glucose were observed with repaglinide (HBA1c: 1.5%, fasting glucose: 2.8 mmol/L, 2-h glucose: 3.7 mmol/L, AUC120: 18.9%) and glibenclamide (1.0%, 2.2 mmol/L, 2.5 mmol/L, 17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress. Conclusion: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.
AB - Aim: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin. Methods: A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120). Results: Significant improvements in glucose were observed with repaglinide (HBA1c: 1.5%, fasting glucose: 2.8 mmol/L, 2-h glucose: 3.7 mmol/L, AUC120: 18.9%) and glibenclamide (1.0%, 2.2 mmol/L, 2.5 mmol/L, 17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress. Conclusion: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.
KW - Adult
KW - Aged
KW - Analysis of Variance
KW - Biological Markers
KW - Blood Glucose
KW - Carbamates
KW - Diabetes Mellitus, Type 2
KW - Drug Administration Schedule
KW - Drug Therapy, Combination
KW - E-Selectin
KW - F2-Isoprostanes
KW - Female
KW - Gastric Inhibitory Polypeptide
KW - Glucagon-Like Peptide 1
KW - Glyburide
KW - Hemoglobin A, Glycosylated
KW - Humans
KW - Hyperglycemia
KW - Hypoglycemic Agents
KW - Incretins
KW - Insulin
KW - Intercellular Adhesion Molecule-1
KW - Interleukin-6
KW - Male
KW - Metformin
KW - Middle Aged
KW - Oxidative Stress
KW - Piperidines
KW - Postprandial Period
KW - Time Factors
KW - Treatment Outcome
KW - Wales
U2 - 10.1016/j.diabres.2011.07.014
DO - 10.1016/j.diabres.2011.07.014
M3 - Journal article
C2 - 21835486
VL - 94
SP - 199
EP - 206
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - 2
ER -
ID: 38186756